Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol...

per Sarah R. Brown, Andrew Hall, Hannah L. Buckley, Louise Flanagan, David Gonzalez de Castro, Kate Farnell, Laura Moss, Rebecca Gregory, Kate Newbold, Yong Du, Glenn Flux, Jonathan Wadsley
Publicat 2019-06-01